JP2020503891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503891A5 JP2020503891A5 JP2019551736A JP2019551736A JP2020503891A5 JP 2020503891 A5 JP2020503891 A5 JP 2020503891A5 JP 2019551736 A JP2019551736 A JP 2019551736A JP 2019551736 A JP2019551736 A JP 2019551736A JP 2020503891 A5 JP2020503891 A5 JP 2020503891A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cells
- cell
- car
- cell according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 16
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 15
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 15
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 11
- 210000000822 natural killer cell Anatomy 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 102000009058 Death Domain Receptors Human genes 0.000 claims 1
- 108010049207 Death Domain Receptors Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 102000003800 Selectins Human genes 0.000 claims 1
- 108090000184 Selectins Proteins 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023017202A JP2023052980A (ja) | 2016-12-09 | 2023-02-07 | 操作されたナチュラルキラー細胞およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662432302P | 2016-12-09 | 2016-12-09 | |
| US62/432,302 | 2016-12-09 | ||
| PCT/EP2017/082292 WO2018104562A1 (en) | 2016-12-09 | 2017-12-11 | Engineered natural killer cells and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023017202A Division JP2023052980A (ja) | 2016-12-09 | 2023-02-07 | 操作されたナチュラルキラー細胞およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503891A JP2020503891A (ja) | 2020-02-06 |
| JP2020503891A5 true JP2020503891A5 (cg-RX-API-DMAC7.html) | 2021-01-21 |
| JP7228900B2 JP7228900B2 (ja) | 2023-02-27 |
Family
ID=60937693
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551736A Active JP7228900B2 (ja) | 2016-12-09 | 2017-12-11 | 操作されたナチュラルキラー細胞およびその使用 |
| JP2023017202A Pending JP2023052980A (ja) | 2016-12-09 | 2023-02-07 | 操作されたナチュラルキラー細胞およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023017202A Pending JP2023052980A (ja) | 2016-12-09 | 2023-02-07 | 操作されたナチュラルキラー細胞およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10799536B2 (cg-RX-API-DMAC7.html) |
| EP (4) | EP3581190B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7228900B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20190114966A (cg-RX-API-DMAC7.html) |
| CN (2) | CN110248669B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017371517B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019011450A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3045386A1 (cg-RX-API-DMAC7.html) |
| DK (2) | DK3581190T3 (cg-RX-API-DMAC7.html) |
| ES (3) | ES2746856T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019006598A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018104562A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10906951B2 (en) * | 2015-07-29 | 2021-02-02 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| EP3484478B1 (en) * | 2016-07-15 | 2025-11-05 | Viracta Subsidiary, Inc. | Histone deacetylase inhibitors for use in immunotherapy |
| BR112019011450A2 (pt) | 2016-12-09 | 2019-10-15 | Onkimmune Ltd | células naturais killer modificadas e uso das mesmas |
| US20210228630A1 (en) * | 2018-05-16 | 2021-07-29 | Research Institute At Nationwide Children's Hospital | Generation of knock-out primary and expanded human nk cells using cas9 ribonucleoproteins |
| CN113164519B (zh) * | 2018-08-01 | 2025-01-10 | 南克维斯特公司 | 用于免疫疗法的基因修饰的包含归巢受体或细胞因子和嵌合抗原受体的四顺反子系统 |
| WO2020047048A1 (en) * | 2018-08-29 | 2020-03-05 | Academia Sinica | Combination of natural killer cells with cyclophosphamide compounds for the treatment of cancer |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| WO2020189942A1 (ko) * | 2019-03-15 | 2020-09-24 | 한국과학기술연구원 | 암 상살 능력이 향상된 면역세포 |
| KR102292657B1 (ko) | 2019-03-15 | 2021-08-24 | 한국과학기술연구원 | 암 상살 능력이 향상된 면역세포 |
| CN109970869A (zh) * | 2019-04-12 | 2019-07-05 | 南京卡提医学科技有限公司 | 一种靶向人trail死亡受体的嵌合受体配体及其应用 |
| EP3958875A4 (en) * | 2019-04-25 | 2023-05-10 | Purdue Research Foundation | MANIPULATED NATURAL KILLER CELLS TARGETING PURINGERIC SIGNALING, THEIR CONSTRUCTS AND METHODS OF USE |
| KR20220093337A (ko) * | 2019-10-31 | 2022-07-05 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | Cd38 녹아웃 일차 및 확장된 인간 nk 세포의 생성 |
| WO2021146521A1 (en) * | 2020-01-16 | 2021-07-22 | Acepodia Biotechnologies Ltd. | A novel cd16+ natural killer cell and a method of culturing cd16+ natural killer cell |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| WO2021209625A1 (en) * | 2020-04-17 | 2021-10-21 | Onk Therapeutics Limited | High potency natural killer cells |
| WO2022045827A1 (ko) * | 2020-08-27 | 2022-03-03 | 주식회사 셀리드 | 신규한 코로나바이러스 재조합 스파이크 단백질, 이를 코딩하는 폴리뉴클레오티드, 상기 폴리뉴클레오티드를 포함하는 벡터 및 상기 벡터를 포함하는 코로나바이러스감염증 예방 또는 치료용 백신 |
| US20240141295A1 (en) | 2020-08-31 | 2024-05-02 | City Of Hope | Novel cell lines, methods of producing natural killer cells and uses thereof |
| CN114426583B (zh) * | 2020-10-29 | 2023-10-10 | 中国科学技术大学 | 用于急性髓系白血病的细胞疗法的嵌合抗原受体 |
| WO2022139517A1 (ko) * | 2020-12-23 | 2022-06-30 | 주식회사 휴먼셀바이오 | 혈액 유래 물질 및 면역세포를 포함하는 암 또는 면역질환의 예방 또는 치료용 약학조성물 |
| EP4355860A1 (en) | 2021-06-18 | 2024-04-24 | ONK Therapeutics Limited | Double knockout natural killer cells |
| WO2023278811A1 (en) | 2021-07-01 | 2023-01-05 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
| WO2023010038A1 (en) * | 2021-07-29 | 2023-02-02 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Synthetic nucleic acid elements for enhancing car t cell efficacy |
| US20250145693A1 (en) * | 2021-09-18 | 2025-05-08 | Sunnybay Biotech, Inc. | Herv-k antibody, cell, vaccine, and drug therapeutics |
| KR20250005564A (ko) * | 2021-12-03 | 2025-01-09 | 유타대학연구재단 | 고선택성 cd229 항원 결합 도메인 및 사용 방법 |
| EP4547269A1 (en) | 2022-06-30 | 2025-05-07 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
| EP4353741A1 (en) | 2022-10-14 | 2024-04-17 | ONK Therapeutics Limited | Double knockout natural killer cells |
| WO2024100203A1 (en) | 2022-11-10 | 2024-05-16 | Onk Therapeutics Limited | Combined therapies using immunomodulating drugs |
| WO2024238387A1 (en) * | 2023-05-12 | 2024-11-21 | Nkmax Co., Ltd. | Method of treating alzheimer's disease with expanded natural killer cells |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025073908A1 (en) | 2023-10-05 | 2025-04-10 | Onk Therapeutics Limited | Optimised il-15 constructs |
| WO2025146467A1 (en) | 2024-01-04 | 2025-07-10 | Onk Therapeutics Limited | Targeted il-15 construct delivery |
| KR20250118299A (ko) | 2024-01-29 | 2025-08-06 | 인하대학교 산학협력단 | 전기자극 시스템을 활용한 자연살해세포의 암세포 살상 능력 증진 방법 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004074320A2 (en) * | 2003-02-14 | 2004-09-02 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
| CA2602375C (en) | 2005-03-23 | 2018-07-24 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
| CA2664740C (en) | 2006-09-26 | 2021-11-16 | Genmab A/S | Combination treatment of cd38-expressing tumors |
| JP2010507366A (ja) | 2006-10-19 | 2010-03-11 | メルク アンド カンパニー インコーポレイテッド | インターロイキン−１３受容体α１の抗体アンタゴニスト |
| GB0724532D0 (en) | 2007-12-17 | 2008-01-30 | Nat Univ Ireland | Trail variants for treating cancer |
| SI2580243T1 (sl) | 2010-06-09 | 2020-02-28 | Genmab A/S | Protitelesa proti humanemu CD38 |
| ES2671004T3 (es) | 2013-03-07 | 2018-06-04 | Baylor College Of Medicine | Dirección a CD138 en cáncer |
| PL3105317T3 (pl) * | 2014-02-14 | 2019-02-28 | Cellectis | Komórki do immunoterapii zaprojektowane do celowania antygenu obecnego zarówno na komórkach odpornościowych, jak i komórkach patologicznych |
| CA2937750A1 (en) * | 2014-02-14 | 2015-08-20 | Bellicum Pharmaceuticals, Inc. | Methods for activating t cells using an inducible chimeric polypeptide |
| US20170335281A1 (en) | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| MX387665B (es) | 2014-12-24 | 2025-03-18 | Aadigen Llc | Péptidos, complejos, moléculas de carga y nanopartículas que contienen los mismos. |
| KR20170100653A (ko) | 2014-12-31 | 2017-09-04 | 안트로제네시스 코포레이션 | 천연 킬러 세포를 사용하여 혈액학적 장애, 고형 종양, 또는 감염 질환을 치료하는 방법 |
| US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| EP3845557B1 (en) | 2015-06-12 | 2023-08-02 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
| JP6961497B2 (ja) | 2015-06-25 | 2021-11-05 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| ES2970269T3 (es) | 2015-07-29 | 2024-05-27 | Onk Therapeutics Ltd | Linfocitos citolíticos naturales modificados y líneas de linfocitos citolíticos naturales que tienen citotoxicidad aumentada |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| BR112019011450A2 (pt) | 2016-12-09 | 2019-10-15 | Onkimmune Ltd | células naturais killer modificadas e uso das mesmas |
-
2017
- 2017-12-11 BR BR112019011450A patent/BR112019011450A2/pt not_active IP Right Cessation
- 2017-12-11 JP JP2019551736A patent/JP7228900B2/ja active Active
- 2017-12-11 ES ES17825774T patent/ES2746856T3/es active Active
- 2017-12-11 WO PCT/EP2017/082292 patent/WO2018104562A1/en not_active Ceased
- 2017-12-11 CN CN201780085686.0A patent/CN110248669B/zh active Active
- 2017-12-11 CA CA3045386A patent/CA3045386A1/en active Pending
- 2017-12-11 DK DK19176141.0T patent/DK3581190T3/da active
- 2017-12-11 EP EP19176141.0A patent/EP3581190B1/en active Active
- 2017-12-11 EP EP22179362.3A patent/EP4104841A1/en active Pending
- 2017-12-11 CN CN202311063691.5A patent/CN117305250A/zh active Pending
- 2017-12-11 AU AU2017371517A patent/AU2017371517B2/en active Active
- 2017-12-11 ES ES19176141T patent/ES2875005T3/es active Active
- 2017-12-11 EP EP21160170.3A patent/EP3895712B1/en active Active
- 2017-12-11 US US15/837,576 patent/US10799536B2/en active Active
- 2017-12-11 MX MX2019006598A patent/MX2019006598A/es unknown
- 2017-12-11 ES ES21160170T patent/ES2926397T3/es active Active
- 2017-12-11 KR KR1020197019363A patent/KR20190114966A/ko not_active Ceased
- 2017-12-11 DK DK17825774.7T patent/DK3454871T3/da active
- 2017-12-11 EP EP17825774.7A patent/EP3454871B1/en active Active
-
2020
- 2020-08-31 US US17/008,506 patent/US20210046118A1/en active Pending
-
2023
- 2023-02-07 JP JP2023017202A patent/JP2023052980A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503891A5 (cg-RX-API-DMAC7.html) | ||
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| JP2016520074A5 (cg-RX-API-DMAC7.html) | ||
| PH12018501778A1 (en) | Antibodies to tigit | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| PH12019502356A1 (en) | Trem2 antigen binding proteins and uses thereof | |
| JP2012254092A5 (cg-RX-API-DMAC7.html) | ||
| JP2014505463A5 (cg-RX-API-DMAC7.html) | ||
| ZA202206437B (en) | Claudin18.2 binding moieties and uses thereof | |
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| JP2017518258A5 (cg-RX-API-DMAC7.html) | ||
| JP2016502515A5 (cg-RX-API-DMAC7.html) | ||
| JP2015535691A5 (cg-RX-API-DMAC7.html) | ||
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| WO2016014565A3 (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
| MX2022003249A (es) | Anticuerpos anti receptor del factor de necrosis tumoral 2 (tnfr2) y métodos de uso. | |
| JP2017513478A5 (cg-RX-API-DMAC7.html) | ||
| JP2014039548A5 (cg-RX-API-DMAC7.html) | ||
| JP2015131795A5 (cg-RX-API-DMAC7.html) | ||
| WO2015142675A8 (en) | Treatment of cancer using chimeric antigen receptor | |
| JP2018524326A5 (cg-RX-API-DMAC7.html) | ||
| HK1210792A1 (en) | Molecules with antigen binding and polyvalent fc gamma receptor binding activity | |
| JP2018509163A5 (cg-RX-API-DMAC7.html) | ||
| JP2017537972A5 (cg-RX-API-DMAC7.html) | ||
| JP2017508466A5 (cg-RX-API-DMAC7.html) |